Stock EMMA EMMAUS LIFE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Emmaus Life Sciences, Inc.

Equities

EMMA

US29137T1016

Delayed OTC Markets
Other stock markets
 03:23:12 2024-07-08 pm EDT 		5-day change 1st Jan Change
0.0752 USD -5.87% Intraday chart for Emmaus Life Sciences, Inc. -17.72% -24.88%
Jul. 03 Emmaus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 02 Emmaus Life Sciences, Inc. Receives Marketing Authorization from the Puerto Rico Department of Health for Endari® (L-Glutamine Oral Powder) CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Emmaus Life Sciences Reports 2023 Financial Results
PR
Emmaus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Emmaus Life Sciences : Certificate of Incorporation/Bylaws - Form 8-K
PU
Emmaus Life Sciences Reports Delayed Filing of Annual Report
PR
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico
PR
Emmaus Life Sciences, Inc. Receives Marketing Authorization from the Puerto Rico Department of Health for Endari® (L-Glutamine Oral Powder)
CI
Emmaus Life Sciences : Material Agreement - Form 8-K
PU
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5M
MT
Emmaus Life Sciences Reports Q3 2023 Financial Results
PR
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Emmaus Life Sciences, Inc. Announces Board Changes
CI
Emmaus Life Sciences Reports Management Changes
PR
Emmaus Life Sciences, Inc. Announces Yutaka Niihara No Longer Serve as Chief Executive Officer
CI
Emmaus Life Sciences, Inc. Announces Management Changes
CI
Emmaus Life Sciences Reports Q2 2023 Financial Results
PR
Emmaus Life Sciences : Reports Q2 2023 Financial Results - Form 8-K
PU
Emmaus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman
PR
Emmaus Life Sciences, Inc Receives Marketing Authorization for Endari® in Oman
CI
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EMMA Stock
  4. News Emmaus Life Sciences, Inc.